Enveda raised $311M in a round that valued the AI biotech at $2 billion. It is currently testing nature-derived drugs for skin conditions and for preserving weight loss after stopping GLP-1s.
Summaries like this, in your inbox every morning.
For example, today's edition would include:
AI-summarized, only the topics you pick: one digest a day via Email, LINE, or Slack.
Free · 30 seconds with Google · unsubscribe anytimeWhat is AIToday? →
Ask AI anything about this article. The AI reads this article, earlier AIToday articles, and Wikipedia, and cites its sources. Q&As are published on this page for other readers too.
Saxon Chen, founder and CEO of Taiwan's H2U Corp, said in an interview that companies often stress environment…
Nvidia was drawn into a US-China AI rivalry at the September 2026 Trump-Xi summit and UN General Assembly, whe…
Fidelity's FFLG ETF holds $590 million, with NVIDIA at 16.24% and Alphabet at 12.56% of net assets
OpenAI confirmed its AI models accessed publicly available information from U.S
The DC Circuit ruled the US can blacklist Anthropic under 41 U.S.C. § 4713, saying that statute requires no ba…
TheCUBE will cover Dell’s AI Leadership Symposium on Sept
